keyword
MENU ▼
Read by QxMD icon Read
search

psychedelic psychotherapy

keyword
https://www.readbyqxmd.com/read/29728331/3-4-methylenedioxymethamphetamine-mdma-assisted-psychotherapy-for-post-traumatic-stress-disorder-in-military-veterans-firefighters-and-police-officers-a-randomised-double-blind-dose-response-phase-2-clinical-trial
#1
Michael C Mithoefer, Ann T Mithoefer, Allison A Feduccia, Lisa Jerome, Mark Wagner, Joy Wymer, Julie Holland, Scott Hamilton, Berra Yazar-Klosinski, Amy Emerson, Rick Doblin
BACKGROUND: Post-traumatic stress disorder (PTSD) is prevalent in military personnel and first responders, many of whom do not respond to currently available treatments. This study aimed to assess the efficacy and safety of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for treating chronic PTSD in this population. METHODS: We did a randomised, double-blind, dose-response, phase 2 trial at an outpatient psychiatric clinic in the USA. We included service personnel who were 18 years or older, with chronic PTSD duration of 6 months or more, and who had a Clinician-Administered PTSD Scale (CAPS-IV) total score of 50 or greater...
April 30, 2018: Lancet Psychiatry
https://www.readbyqxmd.com/read/29674223/psychological-variables-implied-in-the-therapeutic-effect-of-ayahuasca-a-contextual-approach
#2
Alba Franquesa, Alberto Sainz-Cort, Sam Gandy, Joaquim Soler, Miguel Ángel Alcázar-Córcoles, José Carlos Bouso
Ayahuasca is a psychedelic decoction originating from Amazonia. The ayahuasca-induced introspective experience has been shown to have potential benefits in the treatment of several pathologies, to protect mental health and to improve neuropsychological functions and creativity, and boost mindfulness. The underlying psychological processes related to the use of ayahuasca in a psychotherapeutic context are not yet well described in the scientific literature, but there is some evidence to suggest that psychological variables described in psychotherapies could be useful in explaining the therapeutic effects of the brew...
April 4, 2018: Psychiatry Research
https://www.readbyqxmd.com/read/29515449/the-psychedelic-debriefing-in-alcohol-dependence-treatment-illustrating-key-change-phenomena-through-qualitative-content-analysis-of-clinical-sessions
#3
Elizabeth M Nielson, Darrick G May, Alyssa A Forcehimes, Michael P Bogenschutz
Research on the clinical applications of psychedelic-assisted psychotherapy has demonstrated promising early results for treatment of alcohol dependence. Detailed description of the content and methods of psychedelic-assisted psychotherapy, as it is conducted in clinical settings, is scarce. Methods: An open-label pilot (proof-of-concept) study of psilocybin-assisted treatment of alcohol dependence (NCT01534494) was conducted to generate data for a phase 2 RCT (NCT02061293) of a similar treatment in a larger population...
2018: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29515439/clinical-interpretations-of-patient-experience-in-a-trial-of-psilocybin-assisted-psychotherapy-for-alcohol-use-disorder
#4
Michael P Bogenschutz, Samantha K Podrebarac, Jessie H Duane, Sean S Amegadzie, Tara C Malone, Lindsey T Owens, Stephen Ross, Sarah E Mennenga
After a hiatus of some 40 years, clinical research has resumed on the use of classic hallucinogens to treat addiction. Following completion of a small open-label feasibility study, we are currently conducting a double-blind placebo-controlled clinical trial of psilocybin-assisted treatment of alcohol use disorder. Although treatment effects cannot be analyzed until the study is complete, descriptive case studies provide a useful window into the therapeutic process of psychedelic-assisted treatment of addiction...
2018: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29476779/psychedelics-where-we-are-now-why-we-got-here-what-we-must-do
#5
REVIEW
Sean J Belouin, Jack E Henningfield
The purpose of this commentary is to provide an introduction to this special issue of Neuropharmacology with a historical perspective of psychedelic drug research, their use in psychiatric disorders, research-restricting regulatory controls, and their recent emergence as potential breakthrough therapies for several brain-related disorders. It begins with the discovery of lysergic acid diethylamide (LSD) and its promising development as a treatment for several types of mental illnesses during the 1940s. This was followed by its abuse and stigmatization in the 1960s that ultimately led to the placement of LSD and other psychedelic drugs into the most restrictively regulated drug schedule of the United States Controlled Substances Act (Schedule I) in 1970 and its international counterparts...
February 21, 2018: Neuropharmacology
https://www.readbyqxmd.com/read/29461039/dark-classics-in-chemical-neuroscience-lysergic-acid-diethylamide-lsd
#6
David E Nichols
Lysergic acid diethylamide (LSD) is one of the most potent psychoactive agents known, producing dramatic alterations of consciousness after submilligram (≥20 μg) oral doses. Following the accidental discovery of its potent psychoactive effects in 1943, it was supplied by Sandoz Laboratories as an experimental drug that might be useful as an adjunct for psychotherapy, or to give psychiatrists insight into the mental processes in their patients. The finding of serotonin in the mammalian brain in 1953, and its structural resemblance to LSD, quickly led to ideas that serotonin in the brain might be involved in mental disorders, initiating rapid research interest in the neurochemistry of serotonin...
March 1, 2018: ACS Chemical Neuroscience
https://www.readbyqxmd.com/read/29152674/progress-and-promise-for-the-mdma-drug-development-program
#7
REVIEW
Allison A Feduccia, Julie Holland, Michael C Mithoefer
Pharmacotherapy is often used to target symptoms of posttraumatic stress disorder (PTSD), but does not provide definitive treatment, and side effects of daily medication are often problematic. Trauma-focused psychotherapies are more likely than drug treatment to achieve PTSD remission, but have high dropout rates and ineffective for a large percentage of patients. Therefore, research into drugs that might increase the effectiveness of psychotherapy is a logical avenue of investigation. The most promising drug studied as a catalyst to psychotherapy for PTSD thus far is 3,4-methylenedioxymethamphetamine (MDMA), commonly known as the recreational drug "Ecstasy...
February 2018: Psychopharmacology
https://www.readbyqxmd.com/read/29126911/why-mdma-therapy-for-alcohol-use-disorder-and-why-now
#8
REVIEW
Ben Sessa
Alcohol use disorder represents a serious clinical, social and personal burden on its sufferers and a significant financial strain on society. Current treatments, both psychological and pharmacological are poor, with high rates of relapse after medical detoxification and dedicated treatment programs. The earliest historical roots of psychedelic drug-assisted psychotherapy in the 1950s were associated with Lysergic acid diethylamide (LSD)-assisted psychotherapy to treat what was then called, alcoholism. But results were varied and psychedelic therapy with LSD and other 'classical' psychedelics fell out of favour in the wake of socio-political pressures and cultural changes...
November 7, 2017: Neuropharmacology
https://www.readbyqxmd.com/read/29119217/psilocybin-with-psychological-support-for-treatment-resistant-depression-six-month-follow-up
#9
R L Carhart-Harris, M Bolstridge, C M J Day, J Rucker, R Watts, D E Erritzoe, M Kaelen, B Giribaldi, M Bloomfield, S Pilling, J A Rickard, B Forbes, A Feilding, D Taylor, H V Curran, D J Nutt
RATIONALE: Recent clinical trials are reporting marked improvements in mental health outcomes with psychedelic drug-assisted psychotherapy. OBJECTIVES: Here, we report on safety and efficacy outcomes for up to 6 months in an open-label trial of psilocybin for treatment-resistant depression. METHODS: Twenty patients (six females) with (mostly) severe, unipolar, treatment-resistant major depression received two oral doses of psilocybin (10 and 25 mg, 7 days apart) in a supportive setting...
February 2018: Psychopharmacology
https://www.readbyqxmd.com/read/28768346/-psychotherapy-with-adjuvant-use-of-serotonergic-psychoactive-substances-possibilities-and-challenges
#10
Tomislav Majić, Henrik Jungaberle, Timo T Schmidt, Andrea Zeuch, Leo Hermle, Jürgen Gallinat
Background  Recently, scientific interest in the therapeutic potential of serotonergic and psilocybin hallucinogens (psychedelics) such as lysergic acid diethylamide (LSD) and entactogens like 3,4-methylendioxymethamphetamine (MDMA) within the framework of psychotherapy has resumed. The present article provides an overview on the current evidence on substance-assisted psychotherapy with these substances. Method  A selective search was carried out in the PubMed and Cochrane Library including studies investigating the clinical use of serotonergic psychoactive substances since 2000...
July 2017: Fortschritte der Neurologie-Psychiatrie
https://www.readbyqxmd.com/read/28443617/the-therapeutic-potential-of-psychedelic-drugs-past-present-and-future
#11
Robin L Carhart-Harris, Guy M Goodwin
Plant-based psychedelics, such as psilocybin, have an ancient history of medicinal use. After the first English language report on LSD in 1950, psychedelics enjoyed a short-lived relationship with psychology and psychiatry. Used most notably as aids to psychotherapy for the treatment of mood disorders and alcohol dependence, drugs such as LSD showed initial therapeutic promise before prohibitive legislature in the mid-1960s effectively ended all major psychedelic research programs. Since the early 1990s, there has been a steady revival of human psychedelic research: last year saw reports on the first modern brain imaging study with LSD and three separate clinical trials of psilocybin for depressive symptoms...
October 2017: Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28196428/the-association-of-psychedelic-use-and-opioid-use-disorders-among-illicit-users-in-the-united-states
#12
Vincent D Pisano, Nathaniel P Putnam, Hannah M Kramer, Kevin J Franciotti, John H Halpern, Selma C Holden
BACKGROUND: Preliminary studies show psychedelic compounds administered with psychotherapy are potentially effective and durable substance misuse interventions. However, little is known about the association between psychedelic use and substance misuse in the general population. This study investigated the association between psychedelic use and past year opioid use disorders within illicit opioid users. METHODS: While controlling for socio-demographic covariates and the use of other substances, the relationship between classic psychedelic use and past year opioid use disorders was analyzed within 44,000 illicit opioid users who completed the National Survey on Drug Use and Health from 2008 to 2013...
May 2017: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/28019026/psychedelics-as-medicines-an-emerging-new-paradigm
#13
REVIEW
D E Nichols, M W Johnson, C D Nichols
Scientific interest in serotonergic psychedelics (e.g., psilocybin and LSD; 5-HT2A receptor agonists) has dramatically increased within the last decade. Clinical studies administering psychedelics with psychotherapy have shown preliminary evidence of robust efficacy in treating anxiety and depression, as well as addiction to tobacco and alcohol. Moreover, recent research has suggested that these compounds have potential efficacy against inflammatory diseases through novel mechanisms, with potential advantages over existing antiinflammatory agents...
February 2017: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/27435062/ayahuasca-enhances-creative-divergent-thinking-while-decreasing-conventional-convergent-thinking
#14
K P C Kuypers, J Riba, M de la Fuente Revenga, S Barker, E L Theunissen, J G Ramaekers
INTRODUCTION: Ayahuasca is a South American psychotropic plant tea traditionally used in Amazonian shamanism. The tea contains the psychedelic 5-HT2A receptor agonist N,N-dimethyltryptamine (DMT), plus β-carboline alkaloids with monoamine oxidase-inhibiting properties. Increasing evidence from anecdotal reports and open-label studies indicates that ayahuasca may have therapeutic effects in treatment of substance use disorders and depression. A recent study on the psychological effects of ayahuasca found that the tea reduces judgmental processing and inner reactivity, classic goals of mindfulness psychotherapy...
September 2016: Psychopharmacology
https://www.readbyqxmd.com/read/27392130/from-psychiatry-to-flower-power-and-back-again-the-amazing-story-of-lysergic-acid-diethylamide
#15
Hermann A M Mucke
Among the psychedelic drugs that enjoyed a period of popularity in psychiatric research during the 1950s and 1960s, lysergic acid diethylamide (LSD) is the most prominent one. Psychiatrists of that time had seen LSD not only as a tool for psychotherapy but also as a potential therapeutic for anxiety, depression, alcohol abuse, autism, and even schizophrenia. When it became a quasi-religious epitome of the Hippie counterculture in the mid 1960s, and cases of what we now call hallucinogen persisting perception disorder and acute psychotic "flashbacks" mounted, authorities moved to make LSD illegal...
July 8, 2016: Assay and Drug Development Technologies
https://www.readbyqxmd.com/read/27378878/ego-dissolution-and-psychedelics-validation-of-the-ego-dissolution-inventory-edi
#16
Matthew M Nour, Lisa Evans, David Nutt, Robin L Carhart-Harris
AIMS: The experience of a compromised sense of "self", termed ego-dissolution, is a key feature of the psychedelic experience. This study aimed to validate the Ego-Dissolution Inventory (EDI), a new 8-item self-report scale designed to measure ego-dissolution. Additionally, we aimed to investigate the specificity of the relationship between psychedelics and ego-dissolution. METHOD: Sixteen items relating to altered ego-consciousness were included in an internet questionnaire; eight relating to the experience of ego-dissolution (comprising the EDI), and eight relating to the antithetical experience of increased self-assuredness, termed ego-inflation...
2016: Frontiers in Human Neuroscience
https://www.readbyqxmd.com/read/27354909/lysergic-acid-diethylamide-a-drug-of-use
#17
REVIEW
Saibal Das, Preeti Barnwal, Anand Ramasamy, Sumalya Sen, Somnath Mondal
Lysergic acid diethylamide (LSD), described as a classical hallucinogen, began its journey from the middle of the last century following an accidental discovery. Since then, it was used as a popular and notorious substance of abuse in various parts of the world. Its beneficial role as an adjunct to psychotherapy was much unknown, until some 'benevolent' experiments were carried out over time to explore some of its potential uses. But, many of its effects were unclear and seemed to be a psychedelic enigma. In this review article, we have described the receptor pharmacology, mechanism of action, effects and adverse effects of LSD on the normal body system...
June 2016: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/27084302/lsd-modulates-music-induced-imagery-via-changes-in-parahippocampal-connectivity
#18
Mendel Kaelen, Leor Roseman, Joshua Kahan, Andre Santos-Ribeiro, Csaba Orban, Romy Lorenz, Frederick S Barrett, Mark Bolstridge, Tim Williams, Luke Williams, Matthew B Wall, Amanda Feilding, Suresh Muthukumaraswamy, David J Nutt, Robin Carhart-Harris
Psychedelic drugs such as lysergic acid diethylamide (LSD) were used extensively in psychiatry in the past and their therapeutic potential is beginning to be re-examined today. Psychedelic psychotherapy typically involves a patient lying with their eyes-closed during peak drug effects, while listening to music and being supervised by trained psychotherapists. In this context, music is considered to be a key element in the therapeutic model; working in synergy with the drug to evoke therapeutically meaningful thoughts, emotions and imagery...
July 2016: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/27067625/novel-psychopharmacological-therapies-for-psychiatric-disorders-psilocybin-and-mdma
#19
REVIEW
Michael C Mithoefer, Charles S Grob, Timothy D Brewerton
4-phosphorloxy-N,N-dimethyltryptamine (psilocybin) and methylenedioxymethamfetamine (MDMA), best known for their illegal use as psychedelic drugs, are showing promise as therapeutics in a resurgence of clinical research during the past 10 years. Psilocybin is being tested for alcoholism, smoking cessation, and in patients with advanced cancer with anxiety. MDMA is showing encouraging results as a treatment for refractory post-traumatic stress disorder, social anxiety in autistic adults, and anxiety associated with a life-threatening illness...
May 2016: Lancet Psychiatry
https://www.readbyqxmd.com/read/26841800/psychedelics
#20
REVIEW
David E Nichols
Psychedelics (serotonergic hallucinogens) are powerful psychoactive substances that alter perception and mood and affect numerous cognitive processes. They are generally considered physiologically safe and do not lead to dependence or addiction. Their origin predates written history, and they were employed by early cultures in many sociocultural and ritual contexts. After the virtually contemporaneous discovery of (5R,8R)-(+)-lysergic acid-N,N-diethylamide (LSD)-25 and the identification of serotonin in the brain, early research focused intensively on the possibility that LSD and other psychedelics had a serotonergic basis for their action...
April 2016: Pharmacological Reviews
keyword
keyword
72981
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"